Well-curated datasets are essential to evidence based decision making and to the integration of artificial intelligence with human reasoning across disciplines. However, many sources of data remain siloed, unstructured, and/or unavailable for complementary and secondary research. Sysrev was developed to address these issues. First, Sysrev was built to aid in systematic evidence reviews (SER), where digital documents are evaluated according to a well defined process, and where Sysrev provides an easy to access, publicly available and free platform for collaborating in SER projects. Secondly, Sysrev addresses the issue of unstructured, siloed, and inaccessible data in the context of generalized data extraction, where human and machine learning algorithms are combined to extract insights and evidence for better decision making across disciplines. Sysrev uses FAIR - Findability, Accessibility, Interoperability, and Reuse of digital assets - as primary principles in design. Sysrev was developed primarily because of an observed need to reduce redundancy, reduce inefficient use of human time and increase the impact of evidence based decision making. This publication is an introduction to Sysrev as a novel technology, with an overview of the features, motivations and use cases of the tool. Sysrev. com is a FAIR motivated web platform for data curation and SER. Sysrev allows users to create data curation projects called "sysrevs" wherein users upload documents, define review tasks, recruit reviewers, perform review tasks, and automate review tasks. Sysrev is a web application designed to facilitate data curation and SERs. Thousands of publicly accessible Sysrev projects have been created, accommodating research in a wide variety of disciplines. Described use cases include data curation, managed reviews, and SERs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374944 | PMC |
http://dx.doi.org/10.3389/frai.2021.685298 | DOI Listing |
Clin Pharmacokinet
January 2025
Laboratoire de Pharmacologie et Toxicologie, Department of Pharmacology, UR 3801, Reims University Hospital, University of Reims Champagne-Ardenne, 45 rue Cognacq Jay, 51092, Reims Cedex, France.
Background And Objective: Apixaban is increasingly being used for stroke prevention in patients with end-stage kidney disease with atrial fibrillation undergoing haemodialysis, but no pharmacostatistical model is available for dosage adjustment. This study aimed to develop a population pharmacokinetic model of apixaban in these patients to characterise its dialytic clearance and determine optimal dosing regimens and discontinuation timing before surgery.
Methods: Patients received 2.
Target Oncol
January 2025
Pharmacy Service, H. Móstoles, Madrid, Spain.
Background: The reported benefit of poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance in patients with newly diagnosed and platinum (Pt)-sensitive recurrent ovarian cancer (OC) included in randomized clinical trials needs to be corroborated in a less selected population.
Objective: The aim is to increase the evidence on niraparib in a real-world setting.
Methods: This is a retrospective observational study including women with platinum-sensitive relapsed high-grade serous OC who started niraparib maintenance between August 2019 (marketing data, Spain) and May 2022.
Diabetologia
January 2025
MRC Epidemiology Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
Aims/hypothesis: UK standard care for type 2 diabetes is structured diabetes education, with no effects on HbA, small, short-term effects on weight and low uptake. We evaluated whether remotely delivered tailored diabetes education combined with commercial behavioural weight management is cost-effective compared with current standard care in helping people with type 2 diabetes to lower their blood glucose, lose weight, achieve remission and improve cardiovascular risk factors.
Methods: We conducted a pragmatic, randomised, parallel two-group trial.
Data Brief
February 2025
Department of Electrical, Electronic and Communication Engineering, Military Institute of Science and Technology (MIST), Dhaka 1216, Bangladesh.
The dataset represents a significant advancement in Bengali lip-reading and visual speech recognition research, poised to drive future applications and technological progress. Despite Bengali's global status as the seventh most spoken language with approximately 265 million speakers, linguistically rich and widely spoken languages like Bengali have been largely overlooked by the research community. fills this gap by offering a pioneering dataset tailored for Bengali lip-reading, comprising visual data from 150 speakers across 54 classes, encompassing Bengali phonemes, alphabets, and symbols.
View Article and Find Full Text PDFEur J Drug Metab Pharmacokinet
January 2025
College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, 471023, China.
Background And Objective: Total glucosides of paeony (TGP) capsules, tripterygium glycoside tablets (TGT), and celecoxib are commonly used drugs in clinical practice for the treatment of Rheumatoid arthritis (RA). An UPLC-MS/MS method for the analysis of celecoxib in beagle dogs was developed, the herb-drug interactions (HDIs) between TGP and TGT with celecoxib were studied based on pharmacokinetics.
Methods: The method of acetonitrile precipitation was applied to process plasma samples.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!